HopeStage
Back to all studies
CompletedNCT06126497

Ropanicant safety and efficacy study for major depression

About this titleRead the official source — NCT06126497

Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Bellflower and 9 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 5, 2024
Recruitment status
Completed
Enrollment listed in the registry
41
Sponsor
Suven Life Sciences Limited
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06126497
Official title
Show the full official title

An Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bellflower · Orange · Torrance

7 more locations
  • Miami Lakes
  • Decatur
  • Savannah
  • Flowood
  • North Canton
  • Murray
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.

Who is behind this study?

The study sponsor is Suven Life Sciences Limited.

Did this study involve medication?

Yes. The study involved medication, including Ropanicant.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies